Philip Taub

Founded in 2003, HealthPro BioVentures LLC is a life sciences investment bank and strategic advisory firm headquartered in New York City

Ksana Health, Inc. is a mental health technology company based in Eugene, OR. Ksana Health aims to transform mental health care and research by translating tools and findings developed by the University of S Center for Digital Mental Health into digital products and services. Led by Dr. Nick Allen, a professor of clinical psychology, the company provides clients, practitioners, administrators, and researchers with digital tools that continuously measure behavioral health and offer personalized interventions to improve mental health. The company was founded in 2019 by Will Shortt and Nick Allen, who has been the CEO since incorporation.

Tactogen, Inc. develops mental wellness medicines. The American company was founded in 2020 by Matthew Baggott and Luke A. Pustejovsky. Matthew Baggott has been the CEO since 2020.

Palo Santo Inc (Palo Santo) is a venture capital firm founded in 2005 by Timothy J Schlidt and Daniel L. Goldberg. The firm is headquartered in New York.

Bridge Investments LLC (Bridge Investments) is a private equity and venture capital firm founded in 1998 by Robert Goldberg and Daniel Goldberg. The firm is headquartered in Chicago, Illinois.

Madison Dearborn Partners LLC (Madison Dearborn Partners) is a private equity firm founded in 1992 by John A. Canning Jr., Paul J. Finnegan, Samuel M. Mencoff, Robin P. Selati, James N. Perry Jr. and Timothy P. Sullivan. The firm is headquartered in Chicago, Illinois.

Bluestone Capital Partners LP is a private company that provides brokerage services. The company is based in New York, NY. The company was founded by John H. Andreadis, Mark T. Behrman.

Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.